Background illustration for clinical trials search

Paid Clinical Trials Oklahoma City

Discover 570 paid clinical trials in Oklahoma City, Oklahoma. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 570

Meloxicam in Mohs Micrographic Surgery

for

Postoperative Pain, Acute, Skin Cancer

Location: Oklahoma City OK

Sponsor: University of Oklahoma

Sex: All

Age: 18 - 70+

Code: NCT07200544

Recruiting

iAmHealthy Clinical Practice Guideline (CPG)

for

Pediatric Obesity, Rural Health, Clinical Practice Guideline

Location: Oklahoma City OK, Kansas City KS, Omaha NE,

Sponsor: University of Kansas Medical Center

Sex: All

Age: 6 - 11

Code: NCT06888011

Recruiting

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

for

Locally Advanced Urothelial Carcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06524544

Phase3, Recruiting

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

for

Metastatic Colorectal Adenocarcinoma,

Location: Oklahoma City OK, Aurora CO, Columbus OH,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06102902

Phase1, Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for

Locally Advanced Adrenal Cortical Carcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 12+

Code: NCT06900595

Phase2, Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

for

Anatomic Stage I Breast Cancer AJCC v8,

Location: Oklahoma City OK, Wellington KS, Winfield KS,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06876714

Phase3, Recruiting

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for

Castration-Sensitive Prostate Carcinoma,

Location: Oklahoma City OK, Richardson TX, Fort Worth TX,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT06931340

Phase3, Recruiting

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

for

Buccal Mucosa Squamous Cell Carcinoma,

Location: Oklahoma City OK, Westwood KS, Kansas City KS,

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT04333537

Phase2, Phase3, Recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

for

Locally Advanced Cervical Adenocarcinoma,

Location: Oklahoma City OK, Tulsa OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07061977

Phase3, Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for

Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular,

Location: Oklahoma City OK, Fort Worth TX, Dallas TX, Lubbock TX,

Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 30

Code: NCT03126916

Phase3, Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

for

Extensive Stage Lung Small Cell Carcinoma,

Location: Oklahoma City OK, Salina KS, Olathe KS,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT06769126

Phase2, Recruiting

Enhancing Smoking Cessation for African American People Everywhere

for

ESCAPE Intervention+NRT, quitSTART Intervention+NRT, CTRL+NRT

Location: Oklahoma City OK

Sponsor: University of Houston

Sex: All

Age: 18+

Code: NCT07024992

Phase2, Recruiting

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

for

Lung Non-Small Cell Carcinoma

Location: Oklahoma City OK, Cape Girardeau MO, O'Fallon IL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07388524

Phase3, Recruiting

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

for

Ulcerative Colitis, Crohn's Disease

Location: Oklahoma City OK

Sponsor: Takeda

Sex: All

Age: 2 - 17

Code: NCT06405087

Phase3, Recruiting

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia

Location: Oklahoma City OK, Wellington KS, Winfield KS,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 65+

Code: NCT07321652

Phase3, Recruiting

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Oklahoma City OK, Overland Park KS, Fairway KS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Empowering Cessation ACS South Region

for

Smoking Cessation

Location: Oklahoma City OK

Sponsor: University of Oklahoma

Sex: All

Age: 18 - 70+

Code: NCT06820034

Phase2, Phase3, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Oklahoma City OK, Richardson TX, Dallas TX,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for

Pancreatic Neoplasm

Location: Oklahoma City OK, Dallas TX, Little Rock AR,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 50 - 70+

Code: NCT04239573

Recruiting

Paid Clinical Trials Oklahoma City

Filter results

Meloxicam in Mohs Micrographic Surgery

iAmHealthy Clinical Practice Guideline (CPG)

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Interested in new trials?

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Enhancing Smoking Cessation for African American People Everywhere

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Empowering Cessation ACS South Region

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers